P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.
2013 ◽
Vol 138
(3)
◽
pp. 961-965
◽
2011 ◽
2013 ◽
Vol 139
(2)
◽
pp. 441-451
◽
2017 ◽
Vol 26
(6)
◽
pp. e12733
◽
2019 ◽
Keyword(s):